glutathione oxidative stress mycotoxins Controlling entry into mitochondria: potential roles for SLC25A39 in health and (treatment of) disease Frontiers | Natural products for

ASH 2025

It depends on the current health condition of the patient

Ongoing Surveillance During Treatment Once peptide therapy is initiated, ongoing surveillance for malignancy should continue throughout the treatment period and potentially beyond, depending on treatment duration and individual risk factors

Nevertheless, since GSH cannot be administered directlybecause of its insufficient absorption, stability and solubilityanalogues have been obtained, through modifications at the -glutamyl, cysteine and glycine moieties, and/or the functionalisation of the central cysteine, that are able to inhibit the activity of GSTs 69,87,105

D + A)) showed a significant decrease in normal cells by 18.66%, 38.34%, 54.05%, 77.63%, and 62.6%, respectively, and a significant increase in apoptotic cells by 109.72%, 287.93%, 311.59%, 431.93%, and 377.03%, respectively, compared to the control